Deferipron: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
←Membuat halaman berisi '{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443270530 | image = Deferiprone.svg | alt = | width = 120 | caption = <!-- Clinical data --> | pronounce = | tradename = Ferriprox | Drugs.com = {{drugs.com|monograph|deferiprone}} | MedlinePlus = a612016 | DailyMedID = Deferiprone | pregnancy_AU = D | pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Deferip...' Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 95:
}}
'''Deferipron''' adalah obat yang [[pengelatan|mengkelat]] zat besi dan digunakan untuk mengobati kelebihan zat besi pada talasemia mayor.<ref name=savulescu>{{cite journal | vauthors = Savulescu J | title = Thalassaemia major: the murky story of deferiprone | journal = BMJ | volume = 328 | issue = 7436 | pages = 358–9 | date = February 2004 | pmid = 14962851 | pmc = 341373 | doi = 10.1136/bmj.328.7436.358 }}</ref> Obat ini pertama kali disetujui dan diindikasikan untuk digunakan dalam mengobati [[talasemia]] mayor pada tahun 1994<ref>{{cite web | author = Staff | work = Cipla | url = http://www.cipla.com/Home/About-Us/History.aspx | title = Cipla's History | archive-url = https://web.archive.org/web/20151027060707/http://www.cipla.com/Home/About-Us/History.aspx | archive-date = 27 October 2015 }}</ref> dan telah dilisensikan untuk digunakan di [[Uni Eropa]] selama bertahun-tahun sambil menunggu persetujuan di Kanada dan Amerika Serikat.<ref name=savulescu/> Pada tanggal 14 Oktober 2011, obat ini disetujui untuk digunakan di AS berdasarkan program persetujuan yang dipercepat oleh FDA.<ref name="FDA PR">{{cite press release | work = U.S. [[Food and Drug Administration]] (FDA) | title = FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body | date = 14 October 2011 | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm | archive-url = https://web.archive.org/web/20161010225844/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm | archive-date = 10 October 2016 | url-status = dead }} {{PD-notice}}</ref><ref name="FDA approval">{{cite web | title=Drug Approval Package: Ferriprox (deferiprone) Tablet NDA #021825 | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 November 2011 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000TOC.cfm | access-date=20 May 2020}}</ref>
Efek samping yang paling umum termasuk urin berwarna merah kecokelatan (menunjukkan bahwa zat besi dikeluarkan melalui urin), mual (merasa mual), mulas, dan muntah. Efek samping yang kurang umum tetapi lebih serius adalah agranulositosis (kadar granulosit yang sangat rendah, sejenis sel darah putih) dan neutropenia (kadar neutrofil yang rendah, sejenis sel darah putih yang melawan infeksi).<ref name="Ferriprox EPAR">{{cite web | title=Ferriprox EPAR | website=[[European Medicines Agency]] (EMA) | date=28 October 2009 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox | access-date=20 May 2020}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref name="FDA PR" />
| |||